Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CTOR NYSE:IKT NASDAQ:NKTX NASDAQ:TELO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCTORCitius Oncology$1.53-4.4%$2.05$0.55▼$6.19$114.48M3.061.30 million shs573,376 shsIKTInhibikase Therapeutics$1.84-3.2%$1.90$1.12▼$4.20$136.79M0.92280,237 shs93,530 shsNKTXNkarta$1.91-4.5%$1.81$1.31▼$7.24$141.91M0.71.02 million shs1.05 million shsTELOTelomir Pharmaceuticals$2.28+88.4%$1.83$1.12▼$8.40$36.01M-0.9847,241 shs136.65 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCTORCitius Oncology-4.38%-45.74%-1.29%+127.71%+152,999,900.00%IKTInhibikase Therapeutics-3.16%-0.54%+8.24%-2.90%+23.49%NKTXNkarta-4.50%+4.37%+4.95%+5.52%-74.77%TELOTelomir Pharmaceuticals+88.43%+96.55%+29.55%-8.06%-42.42%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCTORCitius Oncology1.644 of 5 stars3.00.00.00.02.91.70.0IKTInhibikase Therapeutics1.2068 of 5 stars3.31.00.00.00.00.00.6NKTXNkarta1.4315 of 5 stars3.60.00.00.00.61.70.6TELOTelomir Pharmaceuticals2.9409 of 5 stars3.83.00.00.01.90.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCTORCitius Oncology 2.00Hold$3.0096.08% UpsideIKTInhibikase Therapeutics 2.50Moderate Buy$6.50253.26% UpsideNKTXNkarta 3.13Buy$14.33650.44% UpsideTELOTelomir Pharmaceuticals 3.50Strong Buy$15.00557.89% UpsideCurrent Analyst Ratings BreakdownLatest TELO, CTOR, NKTX, and IKT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2025NKTXNkartaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$16.00 ➝ $14.005/23/2025CTORCitius OncologyCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeHold5/23/2025CTORCitius OncologyMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/15/2025NKTXNkartaWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform5/15/2025NKTXNkartaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.00(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCTORCitius OncologyN/AN/AN/AN/A$0.64 per shareN/AIKTInhibikase TherapeuticsN/AN/AN/AN/A$1.78 per shareN/ANKTXNkartaN/AN/AN/AN/A$5.78 per shareN/ATELOTelomir PharmaceuticalsN/AN/AN/AN/A$0.02 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCTORCitius OncologyN/AN/A0.00∞N/AN/A-53.88%-18.86%N/AIKTInhibikase Therapeutics-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/ANKTXNkarta-$108.79M-$1.51N/AN/AN/AN/A-26.64%-21.62%8/12/2025 (Estimated)TELOTelomir Pharmaceuticals-$16.53M-$0.42N/AN/AN/AN/A-2,009.40%-1,009.72%8/12/2025 (Estimated)Latest TELO, CTOR, NKTX, and IKT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025NKTXNkarta-$0.37N/AN/AN/AN/AN/A8/12/2025N/ATELOTelomir Pharmaceuticals-$0.08N/AN/AN/AN/AN/A5/14/2025Q2 2025CTORCitius Oncology-$0.09-$0.11-$0.02-$0.11$5.74 millionN/A5/14/2025Q1 2025NKTXNkarta-$0.44-$0.43+$0.01-$0.43N/AN/A5/12/2025Q1 2025TELOTelomir Pharmaceuticals-$0.10-$0.07+$0.03-$0.07N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCTORCitius OncologyN/AN/AN/AN/AN/AIKTInhibikase TherapeuticsN/AN/AN/AN/AN/ANKTXNkartaN/AN/AN/AN/AN/ATELOTelomir PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCTORCitius Oncology0.110.360.05IKTInhibikase TherapeuticsN/A0.850.85NKTXNkartaN/A14.4814.48TELOTelomir PharmaceuticalsN/A0.750.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCTORCitius Oncology70.52%IKTInhibikase Therapeutics3.81%NKTXNkarta80.54%TELOTelomir PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCTORCitius Oncology4.57%IKTInhibikase Therapeutics7.30%NKTXNkarta8.40%TELOTelomir PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCTORCitius OncologyN/A71.55 million68.28 millionN/AIKTInhibikase Therapeutics674.34 million66.18 millionNot OptionableNKTXNkarta14070.96 million65.00 millionOptionableTELOTelomir Pharmaceuticals129.76 millionN/AN/ATELO, CTOR, NKTX, and IKT HeadlinesRecent News About These CompaniesTelomir Pharmaceuticals Skyrockets 150% on Breakthrough Preclinical Cancer ResultsJuly 18 at 2:14 PM | msn.comTelomir Pharmaceuticals stock soars after promising cancer treatment dataJuly 18 at 9:13 AM | investing.comTelomir Pharma Jumps In After-Hours Trading After Drug Reverses Damage In Progeria Cells; Retail Eyes Bigger GainsJuly 18 at 9:13 AM | msn.comTelomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and RapamycinJuly 18 at 8:00 AM | accessnewswire.comATelomir says data show Telomir-1 reversed epigenetic silencingJuly 17 at 12:21 AM | msn.comTelomir Pharmaceuticals Reveals Promising Preclinical Cancer ResultsJuly 17 at 5:14 PM | tipranks.comTelomir Pharmaceuticals Inc News (TELO) - Investing.comJuly 1, 2025 | investing.comTelomir Pharmaceuticals Reports Positive Preclinical DataJune 18, 2025 | tipranks.comTelomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid AgingJune 18, 2025 | accessnewswire.comATelomir Pharma’s Telomir-1 shows dose-dependent restoration of neurological, liver & kidney functions in preclinical for Wilson’s diseaseJune 14, 2025 | pharmabiz.comPTELO Rises on Promising Telomir-1 Preclinical ResultsJune 13, 2025 | insidermonkey.comTELO Rises on Promising Telomir-1 Preclinical ResultsJune 13, 2025 | msn.comTELO Continues Trend of Significant Trial AnnouncementsJune 11, 2025 | msn.comTelomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease ModelJune 11, 2025 | accessnewswire.comATelomir Pharmaceuticals Announces Telomir-1 Resets the Body’s Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated ...June 7, 2025 | usatoday.comTELO Data Indicates Aging Reversal PotentialJune 6, 2025 | finance.yahoo.comTelomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner SyndromeJune 5, 2025 | accessnewswire.comATelomir announces positive preclinical data for its novel oral AMD therapeuticJune 3, 2025 | ophthalmologytimes.comOTelomir Pharmaceuticals Joins BIO Convention for PartnershipsJune 2, 2025 | tipranks.comTelomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity PlatformJune 2, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Semiconductor Stocks Poised to Surge on AI SpendingBy Chris Markoch | June 25, 2025View 3 Semiconductor Stocks Poised to Surge on AI SpendingDon’t Miss These 2 Small Quantum Stocks Poised to PopBy Gabriel Osorio-Mazilli | June 24, 2025View Don’t Miss These 2 Small Quantum Stocks Poised to PopTop 5 Stocks for July: Momentum-Driven Picks to Watch NowBy Thomas Hughes | June 30, 2025View Top 5 Stocks for July: Momentum-Driven Picks to Watch NowJoby vs. Archer: Which eVTOL Stock Is Better for Your Portfolio?By Jeffrey Neal Johnson | July 14, 2025View Joby vs. Archer: Which eVTOL Stock Is Better for Your Portfolio?ASML Keeps Buying Back Its Own Stock—Chasing Discount and UpsideBy Gabriel Osorio-Mazilli | June 25, 2025View ASML Keeps Buying Back Its Own Stock—Chasing Discount and UpsideTELO, CTOR, NKTX, and IKT Company DescriptionsCitius Oncology NASDAQ:CTOR$1.53 -0.07 (-4.38%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.54 +0.00 (+0.33%) As of 07/18/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.Inhibikase Therapeutics NYSE:IKT$1.84 -0.06 (-3.16%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.90 +0.05 (+2.99%) As of 07/18/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.Nkarta NASDAQ:NKTX$1.91 -0.09 (-4.50%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.94 +0.03 (+1.31%) As of 07/18/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.Telomir Pharmaceuticals NASDAQ:TELO$2.28 +1.07 (+88.43%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$2.15 -0.13 (-5.70%) As of 07/18/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
